Women with uterine fibroids who used elagolix (Orilissa) with add-back therapy saw a reduction in heavy menstrual bleeding.
A study was conducted in US and evaluated the safety and efficacy of elagolix at a dose of 300 mg 2 times a day with hormonal add-back therapy in women with bleeding due to fibroids.
The lead investigator stated “Abnormal bleeding is 1 of the most common indications of uterine fibroids and hysterectomy. The oral dose of elagolix with hormonal add-back therapy had a better effect than injectable medication.
Oral therapies, rather than injectables, have more rapid onset and are easier to stop. Injectables last for a longer time—1 or 3 months—and then gradually go away. With an oral medication taken 2 times a day, there is more control by the patient.”
The study results stated “Elagolix with add-back therapy resulted in significant improvements in secondary outcomes, compared with placebo. Improvements included a greater reduction in menstrual blood loss from baseline to the final month, a higher percentage of women with suppression of bleedings at the final month, and a greater reduction in menstrual blood loss from baseline to 6 months and 3 months”.
The study, “Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids,” was published online in The New England Journal of Medicine.
Leave a Reply